Breaking News

Frontage Appoints Clinical Services SVP

May 13, 2014

To expand clinical operations

Eileen McAuley, RN, MPA was named senior vice president, Clinical Services at Frontage. She brings more than 25 years of clinical operations experience, from project management coordination of functional research components to strategic leadership.
 
Ms. McAuley most recently served as chief operating officer of Integrium, a therapeutically-focused, full-service CRO. Previously, she was senior director of Clinical Operations for Alteon, a biotechnology company focused on development of novel treatments for cardiovascular diseases.
 
“We are delighted to welcome Eileen McAuley to our senior leadership team at Frontage. She has exceptional skills in developing sustainable organizational growth, and can offer our clients guidance to effectively manage clinical research programs across multiple therapeutic areas,” said Carlos Orantes, chief operating officer of Frontage Labs. “Ms. McAuley’s leadership abilities and experience will enable Frontage to enhance our service offerings and the overall value we deliver to our clients as we keep pace with the growing complexity of clinical development.”
 
Additionally, Frontage plans to expand its clinical research operations with a new 33,000 sq.-ft. clinical research center in Secaucus, NJ, scheduled to open late in 2014. The new facility will include enhancements to conduct a wider range of clinical studies, as well as multiple, concurrent studies, and will nearly triple the company’s clinical capacity in the U.S.
 
“By expanding our investment and infrastructure in clinical services, Frontage will be well-positioned to comprehensively support the early development needs of our clients,” said Song Li, chief executive officer of Frontage.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016